Skip To Main Content
Mutsuhiro Ikuma on Muck Rack

Mutsuhiro Ikuma

As seen in: Wiley Online Library, ASN Journals
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mutsuhiro

Contact Mutsuhiro, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Conditional early approval for new drug applications in Japan: Current and emerging issues

|
By Mototsugu Tanaka, Ryohei Terashima, Mutsuhiro Ikuma, Haruna Miyazawa
| Wiley Online Library Verified
As have many regulatory agencies in high-income countries, the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA)/Ministry of Health, Labour and Welfare (MHLW) in Japan have implemented expedited programs to improve patients’ access to innovative new drugs for serious diseases without effective therapies.
Open in Who Shared Issue with article?

Role of Roxadustat for ESA-Resistant Renal Anemia? -Read with Caution

|
By Mototsugu Tanaka, Kayo Shinohara, Akiko Ono, Mutsuhiro Ikuma
| ASN Journals Verified
chronic kidney disease hemodialysis hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trial Akizawa et al.1 recently reported a phase-3, double-blind, randomized controlled trial to investigate the efficacy and safety of roxadustat, in comparison to darbepoetin alfa (DA), for renal anemia in Japanese patients on hemodialysis.
Open in Who Shared Issue with article?

Role of Roxadustat for ESA-Resistant Renal Anemia? -Read with Caution

|
By Mototsugu Tanaka, Kayo Shinohara, Akiko Ono, Mutsuhiro Ikuma
| ASN Journals Verified
chronic kidney disease hemodialysis hypoxia-inducible factor erythropoiesis-stimulating agent randomized controlled trial Akizawa et al.1 recently reported a phase-3, double-blind, randomized controlled trial to investigate the efficacy and safety of roxadustat, in comparison to darbepoetin alfa (DA), for renal anemia in Japanese patients on hemodialysis.
Open in Who Shared Issue with article?
See all 4 articles